1,593 Shares in Novo Nordisk A/S (NYSE:NVO) Purchased by Fragasso Financial Advisors Inc

Fragasso Financial Advisors Inc bought a new position in shares of Novo Nordisk A/S (NYSE:NVO) in the 2nd quarter, Holdings Channel.com reports. The firm bought 1,593 shares of the company’s stock, valued at approximately $227,000.

Other institutional investors have also recently made changes to their positions in the company. Cravens & Co Advisors LLC grew its holdings in Novo Nordisk A/S by 1.0% during the 1st quarter. Cravens & Co Advisors LLC now owns 8,250 shares of the company’s stock valued at $1,059,000 after buying an additional 85 shares in the last quarter. Sage Rhino Capital LLC grew its holdings in Novo Nordisk A/S by 0.7% during the 1st quarter. Sage Rhino Capital LLC now owns 12,320 shares of the company’s stock valued at $1,582,000 after buying an additional 89 shares in the last quarter. U.S. Capital Wealth Advisors LLC grew its holdings in Novo Nordisk A/S by 0.6% during the 4th quarter. U.S. Capital Wealth Advisors LLC now owns 15,421 shares of the company’s stock valued at $1,595,000 after buying an additional 90 shares in the last quarter. Essex LLC grew its holdings in Novo Nordisk A/S by 2.0% during the 1st quarter. Essex LLC now owns 4,684 shares of the company’s stock valued at $601,000 after buying an additional 90 shares in the last quarter. Finally, JCIC Asset Management Inc. grew its holdings in Novo Nordisk A/S by 0.3% during the 1st quarter. JCIC Asset Management Inc. now owns 27,552 shares of the company’s stock valued at $3,538,000 after buying an additional 90 shares in the last quarter. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Trading Up 3.3 %

Shares of NVO stock traded up $4.11 on Tuesday, reaching $130.11. 6,988,022 shares of the company’s stock were exchanged, compared to its average volume of 4,429,566. Novo Nordisk A/S has a 52 week low of $79.65 and a 52 week high of $148.15. The company has a current ratio of 0.70, a quick ratio of 0.50 and a debt-to-equity ratio of 0.17. The stock has a market capitalization of $583.87 billion, a PE ratio of 44.87, a P/E/G ratio of 1.33 and a beta of 0.41. The company’s fifty day simple moving average is $138.01 and its 200 day simple moving average is $129.49.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on NVO shares. Argus raised their price target on Novo Nordisk A/S from $125.00 to $160.00 and gave the company a “buy” rating in a report on Monday, June 10th. BMO Capital Markets restated an “outperform” rating and set a $163.00 price target on shares of Novo Nordisk A/S in a report on Tuesday, June 25th. The Goldman Sachs Group initiated coverage on Novo Nordisk A/S in a research note on Thursday, May 30th. They issued a “buy” rating and a $156.00 price objective for the company. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $160.00 price objective on shares of Novo Nordisk A/S in a research note on Monday. Two research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, Novo Nordisk A/S has an average rating of “Moderate Buy” and an average target price of $145.67.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.